Zhou Shengliang, Si Haibo, Peng Linbo, Shen Bin
Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022 Feb 15;36(2):242-248. doi: 10.7507/1002-1892.202109091.
To summarize the role of chondrocytes mitochondrial biogenesis in the pathogenesis of osteoarthritis (OA), and analyze the applications in the treatment of OA.
A review of recent literature was conducted to summarize the changes in mitochondrial biogenesis in the course of OA, the role of major signaling molecules in OA chondrocytes, and the prospects for OA therapeutic applications.
Recent studies reveales that mitochondria are significant energy metabolic centers in chondrocytes and its dysfunction has been considered as an essential mechanism in the pathogenesis of OA. Mitochondrial biogenesis is one of the key processes maintaining the normal quantity and function of mitochondria, and peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α) is the central regulator of this process. A regulatory network of mitochondrial biogenesis with PGC-1α as the center, adenosine monophosphate-activated protein kinase, sirtuin1/3, and cyclic adenosine monophosphate response element-binding protein as the main upstream regulatory molecules, and nuclear respiratory factor 1, estrogen-related receptor α, and nuclear respiratory factor 2 as the main downstream regulatory molecules has been reported. However, the role of mitochondrial biogenesis in OA chondrocytes still needs further validation and in-depth exploration. It has been demonstrated that substances such as puerarin and omentin-1 can retard the development of OA by activating the damaged mitochondrial biogenesis in OA chondrocytes, which proves the potential to be used in the treatment OA.
Mitochondrial biogenesis in chondrocytes plays an important role in the pathogenesis of OA, and further exploring the related mechanisms is of great clinical significance.
总结软骨细胞线粒体生物合成在骨关节炎(OA)发病机制中的作用,并分析其在OA治疗中的应用。
对近期文献进行综述,以总结OA病程中线粒体生物合成的变化、OA软骨细胞中主要信号分子的作用以及OA治疗应用的前景。
近期研究表明,线粒体是软骨细胞中重要的能量代谢中心,其功能障碍被认为是OA发病机制中的一个重要机制。线粒体生物合成是维持线粒体正常数量和功能的关键过程之一,过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)是这一过程的核心调节因子。据报道,以PGC-1α为中心,以腺苷酸活化蛋白激酶、沉默调节蛋白1/3和环磷酸腺苷反应元件结合蛋白为主要上游调节分子,以核呼吸因子1、雌激素相关受体α和核呼吸因子2为主要下游调节分子的线粒体生物合成调控网络。然而,线粒体生物合成在OA软骨细胞中的作用仍需进一步验证和深入探索。已证明,葛根素和网膜素-1等物质可通过激活OA软骨细胞中受损的线粒体生物合成来延缓OA的发展,这证明了其在OA治疗中的应用潜力。
软骨细胞中的线粒体生物合成在OA发病机制中起重要作用,进一步探索相关机制具有重要的临床意义。